ER+/HER2- breast cancer

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  

ER+/HER2- breast cancer
Nov 3, 2024, 16:08 | Insight
Yakup Ergün: Benefit of systemic therapy in MINDACT patients with small ER+ HER2- Breast Cancer
Yakup Ergün, Medical Oncologist at Bower Hospital, shared a post on X about a recent…
Jul 15, 2024, 12:03 | Insight
Aleix Prat: Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
Aleix Prat, Head of the Medical Oncology Department at Hospital Clínic Barcelona, shared a post…
Apr 25, 2024, 21:06 | Drugs
Piotr Wysocki: Datopotamab deruxtecan – another anti-TROP2 conjugate demonstrating activity in advanced ER+/HER2- and triple-negative breast cancer patients
Piotr Wysocki recently shared on LinkedIn: "Datopotamab deruxtecan – a novel anti-TROP2 conjugate demonstrates activity…
Mar 27, 2024, 10:07 | Insight
Piotr Wysocki: No benefit of continuing CDK4/6i beyond progression in advanced ER+/HER2- breast cancer
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Mar 14, 2024, 19:28 | Drugs
François-Clément Bidard: A prospective study to document the efficacy of the combo Fulvestrant+Everolimus
Erika Hamilton, Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, shared…
Feb 9, 2024, 17:30 | Blog
Chris Boshoff: The U.S. FDA has granted Fast Track designation for our investigational treatment for ER+/HER2- breast cancer
Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, posted on LinkedIn: "I’m…
All: 6 Posts: 1 - 100
Special Coverage